Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo.

Bullen CK, Laird GM, Durand CM, Siliciano JD, Siliciano RF.

Nat Med. 2014 Apr;20(4):425-9. doi: 10.1038/nm.3489.

2.

Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations.

Laird GM, Bullen CK, Rosenbloom DI, Martin AR, Hill AL, Durand CM, Siliciano JD, Siliciano RF.

J Clin Invest. 2015 May;125(5):1901-12. doi: 10.1172/JCI80142.

3.

Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients.

Spivak AM, Bosque A, Balch AH, Smyth D, Martins L, Planelles V.

Antimicrob Agents Chemother. 2015 Oct;59(10):5984-91. doi: 10.1128/AAC.01077-15.

4.

The histone deacetylase inhibitor vorinostat (SAHA) increases the susceptibility of uninfected CD4+ T cells to HIV by increasing the kinetics and efficiency of postentry viral events.

Lucera MB, Tilton CA, Mao H, Dobrowolski C, Tabler CO, Haqqani AA, Karn J, Tilton JC.

J Virol. 2014 Sep;88(18):10803-12. doi: 10.1128/JVI.00320-14.

5.

Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat.

Olesen R, Vigano S, Rasmussen TA, Søgaard OS, Ouyang Z, Buzon M, Bashirova A, Carrington M, Palmer S, Brinkmann CR, Yu XG, Østergaard L, Tolstrup M, Lichterfeld M.

J Virol. 2015 Oct;89(20):10176-89. doi: 10.1128/JVI.01484-15.

6.

An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression.

Darcis G, Kula A, Bouchat S, Fujinaga K, Corazza F, Ait-Ammar A, Delacourt N, Melard A, Kabeya K, Vanhulle C, Van Driessche B, Gatot JS, Cherrier T, Pianowski LF, Gama L, Schwartz C, Vila J, Burny A, Clumeck N, Moutschen M, De Wit S, Peterlin BM, Rouzioux C, Rohr O, Van Lint C.

PLoS Pathog. 2015 Jul 30;11(7):e1005063. doi: 10.1371/journal.ppat.1005063.

7.

Targeting HIV latency: pharmacologic strategies toward eradication.

Xing S, Siliciano RF.

Drug Discov Today. 2013 Jun;18(11-12):541-51. doi: 10.1016/j.drudis.2012.12.008. Review.

8.

Synergistic Activation of Latent HIV-1 Expression by Novel Histone Deacetylase Inhibitors and Bryostatin-1.

Martínez-Bonet M, Clemente MI, Serramía MJ, Muñoz E, Moreno S, Muñoz-Fernández MÁ.

Sci Rep. 2015 Nov 13;5:16445. doi: 10.1038/srep16445.

9.

Discovery of a small molecule agonist of phosphatidylinositol 3-kinase p110α that reactivates latent HIV-1.

Doyon G, Sobolewski MD, Huber K, McMahon D, Mellors JW, Sluis-Cremer N.

PLoS One. 2014 Jan 29;9(1):e84964. doi: 10.1371/journal.pone.0084964.

10.

Bryostatin-1 synergizes with histone deacetylase inhibitors to reactivate HIV-1 from latency.

Pérez M, de Vinuesa AG, Sanchez-Duffhues G, Marquez N, Bellido ML, Muñoz-Fernandez MA, Moreno S, Castor TP, Calzado MA, Muñoz E.

Curr HIV Res. 2010 Sep;8(6):418-29.

PMID:
20636281
11.

Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing.

Wei DG, Chiang V, Fyne E, Balakrishnan M, Barnes T, Graupe M, Hesselgesser J, Irrinki A, Murry JP, Stepan G, Stray KM, Tsai A, Yu H, Spindler J, Kearney M, Spina CA, McMahon D, Lalezari J, Sloan D, Mellors J, Geleziunas R, Cihlar T.

PLoS Pathog. 2014 Apr 10;10(4):e1004071. doi: 10.1371/journal.ppat.1004071.

12.

An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients.

Spina CA, Anderson J, Archin NM, Bosque A, Chan J, Famiglietti M, Greene WC, Kashuba A, Lewin SR, Margolis DM, Mau M, Ruelas D, Saleh S, Shirakawa K, Siliciano RF, Singhania A, Soto PC, Terry VH, Verdin E, Woelk C, Wooden S, Xing S, Planelles V.

PLoS Pathog. 2013;9(12):e1003834. doi: 10.1371/journal.ppat.1003834.

13.

Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation.

Rasmussen TA, Schmeltz Søgaard O, Brinkmann C, Wightman F, Lewin SR, Melchjorsen J, Dinarello C, Østergaard L, Tolstrup M.

Hum Vaccin Immunother. 2013 May;9(5):993-1001. doi: 10.4161/hv.23800.

14.

Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations.

Deng K, Pertea M, Rongvaux A, Wang L, Durand CM, Ghiaur G, Lai J, McHugh HL, Hao H, Zhang H, Margolick JB, Gurer C, Murphy AJ, Valenzuela DM, Yancopoulos GD, Deeks SG, Strowig T, Kumar P, Siliciano JD, Salzberg SL, Flavell RA, Shan L, Siliciano RF.

Nature. 2015 Jan 15;517(7534):381-5. doi: 10.1038/nature14053.

15.

Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation.

Xing S, Bullen CK, Shroff NS, Shan L, Yang HC, Manucci JL, Bhat S, Zhang H, Margolick JB, Quinn TC, Margolis DM, Siliciano JD, Siliciano RF.

J Virol. 2011 Jun;85(12):6060-4. doi: 10.1128/JVI.02033-10.

16.

Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.

Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, Parker DC, Anderson EM, Kearney MF, Strain MC, Richman DD, Hudgens MG, Bosch RJ, Coffin JM, Eron JJ, Hazuda DJ, Margolis DM.

Nature. 2012 Jul 25;487(7408):482-5. doi: 10.1038/nature11286. Erratum in: Nature. 2012 Sep 20;489(7416):460.

17.

Activation of latent HIV using drug-loaded nanoparticles.

Kovochich M, Marsden MD, Zack JA.

PLoS One. 2011 Apr 5;6(4):e18270. doi: 10.1371/journal.pone.0018270.

18.
19.

Finding a cure for HIV: will it ever be achievable?

Lewin SR, Evans VA, Elliott JH, Spire B, Chomont N.

J Int AIDS Soc. 2011 Jan 24;14:4. doi: 10.1186/1758-2652-14-4.

20.

Gnidimacrin, a Potent Anti-HIV Diterpene, Can Eliminate Latent HIV-1 Ex Vivo by Activation of Protein Kinase C β.

Lai W, Huang L, Zhu L, Ferrari G, Chan C, Li W, Lee KH, Chen CH.

J Med Chem. 2015 Nov 12;58(21):8638-46. doi: 10.1021/acs.jmedchem.5b01233.

Items per page

Supplemental Content

Support Center